Vaishali Pharma Limited (VAISHALI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vaishali Pharma Limited (VAISHALI) has a cash flow conversion efficiency ratio of 0.030x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs20.46 Million ≈ $221.23K USD) by net assets (Rs673.82 Million ≈ $7.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vaishali Pharma Limited defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Vaishali Pharma Limited - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Vaishali Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vaishali Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaishali Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eastern Technical Engineering Public Company Limited
BK:ETE
|
0.021x |
|
Welcron Hantec Co.Ltd
KQ:076080
|
-1.076x |
|
Bawat Water Technologies AB
ST:BAWAT
|
0.190x |
|
Mercury Industries Bhd
KLSE:8192
|
-0.020x |
|
hGears AG
XETRA:HGEA
|
-0.050x |
|
Opus One Resources Inc
V:OOR
|
-0.055x |
|
Immolease Trust NV
BR:DIEG
|
N/A |
|
Trinity Biotech plc
NASDAQ:TRIB
|
0.001x |
Annual Cash Flow Conversion Efficiency for Vaishali Pharma Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of Vaishali Pharma Limited from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see VAISHALI company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs649.16 Million ≈ $7.02 Million |
Rs-180.38 Million ≈ $-1.95 Million |
-0.278x | -1575.62% |
| 2024-03-31 | Rs428.39 Million ≈ $4.63 Million |
Rs8.07 Million ≈ $87.24K |
0.019x | -29.31% |
| 2023-03-31 | Rs405.31 Million ≈ $4.38 Million |
Rs10.80 Million ≈ $116.77K |
0.027x | -46.76% |
| 2022-03-31 | Rs263.54 Million ≈ $2.85 Million |
Rs13.19 Million ≈ $142.60K |
0.050x | -44.23% |
| 2021-03-31 | Rs224.19 Million ≈ $2.42 Million |
Rs20.11 Million ≈ $217.49K |
0.090x | -40.41% |
| 2020-03-31 | Rs213.81 Million ≈ $2.31 Million |
Rs32.19 Million ≈ $348.11K |
0.151x | +13.11% |
| 2019-03-31 | Rs213.99 Million ≈ $2.31 Million |
Rs28.48 Million ≈ $308.01K |
0.133x | +128.99% |
| 2018-03-31 | Rs206.02 Million ≈ $2.23 Million |
Rs-94.60 Million ≈ $-1.02 Million |
-0.459x | -308.54% |
| 2017-03-31 | Rs38.69 Million ≈ $418.36K |
Rs8.52 Million ≈ $92.12K |
0.220x | -84.38% |
| 2016-03-31 | Rs32.54 Million ≈ $351.88K |
Rs45.88 Million ≈ $496.16K |
1.410x | +222.75% |
| 2015-03-31 | Rs32.35 Million ≈ $349.85K |
Rs-37.16 Million ≈ $-401.89K |
-1.149x | +49.84% |
| 2014-03-31 | Rs30.74 Million ≈ $332.40K |
Rs-70.40 Million ≈ $-761.32K |
-2.290x | -267.26% |
| 2013-03-31 | Rs27.73 Million ≈ $299.89K |
Rs37.97 Million ≈ $410.64K |
1.369x | -- |
About Vaishali Pharma Limited
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti"malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-vir… Read more